Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Net Cash Flow (2022 - 2025)

Envoy Medical's Net Cash Flow history spans 4 years, with the latest figure at -$1.7 million for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 164.58% year-over-year to -$1.7 million; the TTM value through Sep 2025 reached -$870000.0, up 92.99%, while the annual FY2024 figure was $1.3 million, 68.57% down from the prior year.
  • Net Cash Flow for Q3 2025 was -$1.7 million at Envoy Medical, down from -$23000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $16.8 million in Q3 2023 and bottomed at -$12.6 million in Q4 2023.
  • The 4-year median for Net Cash Flow is -$23000.0 (2025), against an average of $174866.7.
  • The largest YoY upside for Net Cash Flow was 4189.71% in 2023 against a maximum downside of 2904.76% in 2023.
  • A 4-year view of Net Cash Flow shows it stood at -$420000.0 in 2022, then crashed by 2904.76% to -$12.6 million in 2023, then soared by 108.4% to $1.1 million in 2024, then tumbled by 263.21% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Net Cash Flow are -$1.7 million (Q3 2025), -$23000.0 (Q2 2025), and -$177000.0 (Q1 2025).